Posted by Michael Wonder on 01 Aug 2023
PHARMAC considers access criteria for COVID-19 anti-viral treatments
1 August 2023 - PHARMAC is consulting on changes to the access criteria for all COVID-19 anti-viral treatments to include more people who are at risk of becoming severely ill from the infection.
The consultation will affect nirmatrelvir with ritonavir (Paxlovid), remdesivir (Veklury) and molnupiravir (Lagevrio).
